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Prévalence du syndrome des jambes sans repos chez les donneuses de sang, une semaine après 
un don de sang – Résumé de l’étude  
 
Le syndrome des jambes sans repos (SJSR) est une pathologie fréquente dont la prévalence dans la 
population générale est de 5-15%. Le SJSR se caractérise par un besoin impérieux de bouger les 
membres inférieurs qui apparaît le plus souvent au repos, le soir et la nuit. Les symptômes sont 
typiquement atténués par la mobilisation des jambes. Plusieurs études ont montré que le SJSR a 
d’importantes répercussions sur le quotidien des patients atteints avec une diminution de leur 
qualité de vie, des troubles du sommeil et une altération des fonctions cognitives. 
 
Un lien entre la carence martiale et le SJSR est supposé depuis plusieurs dizaines d’années. Il a été 
montré que les symptômes sont aggravés en cas de déficit en fer sans qu’une corrélation directe ait 
pu être établie, le taux de ferritine étant souvent normal chez les patients avec un SJRS. Des études 
plus récentes ont permis de montrer qu’il existe une carence en fer au niveau du système nerveux 
central des patients avec un SJSR notamment au niveau du liquide céphalo-rachidien et de la 
substance noire. Il existe une probable dysfonction du système dopaminergique qui explique la 
symptomatologie des patients et la réponse souvent favorable aux agonistes dopaminergiques. Par 
ailleurs, des études ont récemment montré qu’il existe des polymorphismes de plusieurs gènes 
chez les patients avec un SJSR faisant supposer une probable prédisposition génétique.   
 
Les femmes donnant leur sang, population préalablement en bonne santé, sont plus à risque de 
présenter une carence en fer qui pourrait être associée à une augmentation du risque de 
développer un SJSR. Les études à ce sujet ont montré des résultats contradictoires. Une étude 
suédoise parue en 2004 montrait une prévalence du SJSR chez les donneuses de sang de presque 
25% alors qu’une étude américaine de 2010 décrivait une prévalence de 9% comparable à la 
population générale. Il est donc d’intérêt de savoir si l’on fait prendre un risque aux donneuses de 
sang de développer une affection invalidante telle que le SJSR. 
 
Le but de ce travail de thèse en médecine était donc de déterminer la prévalence du SJSR chez les 
donneuses de sang. Une semaine après un don de sang, on demandait aux sujettes de répondre aux 
quatre questions diagnostics définies par le 1995 International RLS study group (groupe d’expert sur 
le SJSR). Le diagnostic de SJSR était retenu en cas de réponse positive aux quatre questions. Dans 
les objectifs secondaires, nous avons également évalué l’hyperménorrhée, la fatigue, la capacité 
aérobique, la fréquence des dons et la qualité de vie et les paramètres hématologiques.    
 
Notre étude s’est déroulée de 2008 à 2010 et notre collectif comprenait 291 donneuses de sang de 
18 à 49 ans. Nos résultats ont montré une prévalence du SJSR de 6.9% chez les donneuses de sang. 
La prévalence de l’hyperménorrhée était augmentée chez les donneuses avec un SJSR et elles 
étaient également significativement plus fatiguées. Nous n’avons pas montré d’association entre le 
SJSR et la capacité aérobique, la fréquence des dons et la qualité de vie. Comme montré dans 
plusieurs études, nous avons confirmé l’absence de lien entre le SJSR et le taux d’hémoglobine et la 
ferritine.  
 
En conclusion, notre étude a permis de montrer une prévalence du SJSR chez les donneuses de sang 
comparable à celle de la population générale. Elle n’est donc pas aussi importante que décrite dans 
certaines études ce qui devrait rassurer les donneuses. Une association entre le SJSR et 
l’hyperménorrhée et la fatigue devrait nous encourager à les dépister chez les donneuses de sang. 
 
A noter finalement que parallèlement à ce volet de notre étude présenté dans cette thèse, nous 
avons également cherché à évaluer l’efficacité d’un traitement substitutif de fer chez les donneuses 
de sang présentant une carence en fer sans anémie, sujet de deux autres articles. 
Vox Sanguinis (2013)
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Background and Objective Restless legs syndrome (RLS) is a frequent condition
with a prevalence of 5–15% in the general population. Clinical and genetic
observations have shown that iron deficiency, highly prevalent among blood
donors, can be related to RLS. The objective of this study was to assess the prev-
alence of RLS in female blood donors 1 week after blood donation.
Methods One week after blood donation, 291 female blood donors, aged
<50 years, self-responded to all four RLS questions defined by the 1995 Interna-
tional RLS study group. Blood donation rate, fatigue, aerobic capacity, menstrua-
tion, mood disorder and quality of life were also assessed along with
haemoglobin and ferritin blood concentrations.
Results Prevalence of RLS in female blood donors 1 week after blood donation was
69% (CI 95% 42–104%). Female blood donors with RLS had a higher prevalence
of hyper-menorrhaea (P = 0033) and were significantly more tired (P = 0001).
We observed no associations between RLS and number of previous donations
(P = 0409), aerobic capacity (P = 0476), mood disorder (P = 0169), quality of life
(P = 0356), haemoglobin (P = 0087), and serum ferritin level (P = 0446).
Conclusion Restless legs syndrome prevalence in female blood donors is not as
important as described in some other studies, which could reassure blood donors.
The prevalence of hypermenorrhaea and fatigue is higher in RLS blood donors.
Therefore, screening for fatigue and hypermenorrhaea could be considered as
these symptoms are associated with RLS in female blood donors.
Key words: blood donation, fatigue, hypermenorrhaea, iron deficiency, restless
legs syndrome, sleep disorder.
Introduction
Restless legs syndrome (RLS) is characterized by an urge
to move the legs, often associated with paresthesias.
Symptoms usually appear while the patient is at rest,
lying down or sitting. The symptoms get worse in the
evening and at night, and are typically relieved by volun-
tarily moving the legs.
Restless legs syndrome prevalence in the general popu-
lation is 5–15% [1–5]. The REST study, a large multicen-
tric prevalence study including five European countries
and the USA, showed a prevalence of RLS of any fre-
quency of 72% in a study population of 16 202 adults
[2]. There was no significant difference between countries.
This study also showed that the prevalence was twice as
high among women, which was confirmed in other stud-
ies [2, 5–7]. Restless legs syndrome has important impli-
cations in everyday life. Sleeping impairment, diminished
cognitive functions and reduced quality of life have been
described [2, 6].
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A link between iron deficiency and RLS was suggested
in the sixties by Ekbom [8], a pioneer in the study of this
disease. Symptom severity has been correlated with serum
ferritin levels <50 lg/l [9]. A study in which the ferritin
level was measured in cerebral spinal fluid (CSF) showed
lower concentrations in RLS patients [10]. Another study
estimating cerebral iron load with magnetic resonance
imaging (MRI) demonstrated decreased iron in the sub-
stantia nigra [11]. Furthermore, Stefansson found a
genetic link between iron deficiency and RLS [12], which
was confirmed in blood donors by Sorenson [13].
Because of iron loss related to blood donation [14],
RLS could be more prevalent in blood donors. A
Swedish study [15] showed a markedly increased preva-
lence of RLS among female blood donors (247%) and,
according to a clinical trial [16] carried out by the same
group of researchers, administration of intravenous iron
relieved these symptoms. However, the association with
blood donation was not confirmed in an American study
[17], which showed a similar prevalence of RLS in
donors compared with the general population (9%). A
recent study also showed a prevalence of RLS of 9% in
donors [18].
These contradictory results are important to clarify.
Potential blood donors may stop giving blood if they are
exposed to the risk of developing a disabling condition
such as RLS [1, 6, 19, 20]. We studied childbearing-aged
female blood donors who are particularly at risk of iron
deficiency. We assessed the prevalence of RLS in Switzer-
land a week after blood donation, when both haemoglo-
bin and ferritin are supposed to be at their lowest levels,
and a possible association with menstrual bleeding, num-
ber of donations in the previous year and biological
parameters (ferritin, haemoglobin). We also assessed the
association of RLS with fatigue, aerobic capacity, mood
and quality of life.
Methods
Study design
This was a nested prevalence study within a randomized
controlled trial [21]. The purpose of the latter study was
to evaluate the clinical effect of an iron treatment among
non-anaemic but iron-deficient female blood donors.
Participants
All consecutive women attending the Lausanne Blood
Transfusion Service of the Swiss Red Cross, aged
18–50 years, and who met eligibility criteria for blood
donation according to Swiss national regulations, were
invited to participate in a clinical trial investigating iron
deficiency in female blood donors. Exclusion criteria were
psychiatric conditions or diseases that rendered the par-
ticipant unable to give consent; thyroid, hepatic, rheu-
matic, kidney, cardiopulmonary, or intestinal disease;
acute or chronic inflammation; diabetes; hemochromato-
sis; pregnancy; medical treatment that could alter iron
absorption and any iron supplementation [22].
Subjects were recruited at Lausanne’s Blood Transfu-
sion Service of the Swiss Red Cross during their usual
visit. In Switzerland, blood is donated on a voluntary
basis without any financial benefit to the donor. Subjects
were women, aged 18–50 years, eligible to donate blood
according to the eligibility criteria of the Swiss Red Cross.
One week after their blood donation, volunteers were then
followed-up by two nurse practitioners at the Department
of Ambulatory Care and Community Medicine of Lau-
sanne University Hospital.
Criteria for clinically-relevant RLS were defined by
positive responses to all four questions defined by the
1995 International RLS study group [23] (Table 1).
Possible RLS was defined as those who responded posi-
tively to the first question, but not to all the other ques-
tions, as it has been suggested that milder or subclinical
forms of RLS might exist [7]. Controls were those who
responded negatively to the first question.
On the same day of the blood donation, we collected
information on age, number of previous blood donations
during the past year, past medical history, medications
taken, biological markers (haemoglobin and ferritin), and
Fatigue Severity Scale (FSS) [24]. One week after dona-
tion, patients self-responded to the four RLS questions
defined by the 1995 International RLS Study Group [23]
and completed Janssen’s Pictorial Bleeding Assessment
Chart [25] to detect hypermenorrhea (cut-off point set at
100 points [26]), the Patient Health Questionnaire (PHQ-9)
Table 1 Restless legs syndrome (RLS) four questions defined by the
1995 International RLS study group [23]
1. An urge to move the legs, usually accompanied or caused by
uncomfortable and unpleasant sensations in the legs (Sometimes the
urge to move is present without the uncomfortable sensations and
sometimes the arms or other body parts are involved in addition to
the legs)
2. The urge to move or unpleasant sensations begin or worsen during
periods of rest or inactivity such as lying or sitting
3. The urge to move or unpleasant sensations are partially or totally
relieved by movement, such as walking or stretching, at least as long
as the activity continues
4. The urge to move or unpleasant sensations are worse in the evening
or night than during the day or only occur in the evening or night
(When symptoms are very severe, the worsening at night may not be
noticeable but must have been previously present)
© 2013 International Society of Blood Transfusion
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[27] to detect mood disorders, and the short form (SF-12)
[28] to measure quality of life (defined as the sum of the
physical and mental health scores). Aerobic capacity was
measured with a step test (Chester Step Test) [29] as an
objective measure of muscular fatigue. Haemoglobin, fer-
ritin, FSS and a fatigue Visual Analogical Scale were also
collected at that time-point. C-reactive protein (CRP) level
was added to exclude increased ferritin owing to inflam-
mation.
Statistical methods
We wished the study detect a fourfold odd ratio of RLS
for those with low ferritin level compared with those with
higher ferritin level. From previous studies, the preva-
lence of blood donors with low ferritin (<15 lg/l) was
assumed to be approximatively 20%. We therefore pow-
ered the study to detect a difference from 20% of RLS in
the low ferritin group compared with 5% of RLS in other
donors with a ratio of 1/5 in the number of donors in
each group. With a significance level set to 005 and a
power of 080, this required including 45 donors with low
ferritin and 224 donors with high ferritin. Assuming 10%
of missing data, 296 participants were to be included. The
study was nested within a clinical trial. Full data were
therefore obtained from 291 participants.
The prevalence of RLS was measured with 95% confi-
dence intervals (CI). Subjects were classified into one of
three groups; no RLS, possible RLS, and definite RLS.
Pre- and postdonation averages of measures were com-
pared between groups using one-way analysis of variance
(ANOVA). For nominal characteristics, we used Fisher’s
exact test. Results were confirmed using a non-parametric
test (Mann–Whitney). Logistic regression was used to
measure the odds of having RLS at 1 week. For multivari-
ate analysis, determinants that showed a significance
level of P < 02 were retained. Missing data were not
replaced. The study obtained ethical approval from the
official biomedical state ethics committee under the refer-
ence 131/08.
Results
A total of 736 female blood donors were invited to par-
ticipate and 313 gave their informed consent prior to
donation between December 2008 and September 2010.
Twenty-two participants did not answer the RLS ques-
tionnaire 1 week after donation; thus, 291 women were
included in the study. The main reason (79%) for non-
participation was lack of availability for personal reasons.
The mean age of the participants was 311 [SD = 92;
range (18–515)] years, and the average frequency of
blood donation during the past year was 09 [SD = 08;
range (0–3)] times. Further description of the blood
donors is provided in Table 2.
One week after blood donation, 20 of the 291 donors
responded positively to all four questions defined by the
1995 International RLS Study Group. The observed preva-
lence of clinically relevant RLS was, therefore, 69%. The
prevalence in the possible RLS group was of 206% (60 of
the 291 donors). One week after blood donation, preva-
lence of ferritin below 30 lg/l was 856% (249), below
25 lg/l was 773% (225), below 15 lg/l was 519% (151).
Donors with RLS reported higher levels of fatigue
(P = 0001) and blood loss due to menstruation
(P = 0033) compared with those without RLS. We did
not observe any significant differences between groups
for number of previous donations, levels of ferritin or
haemoglobin, aerobic capacity, or quality of life (Table 2).
Hypermenorrhaea, FSS scores, depression measured with
the PHQ-9, and the SF-12 mental health scores were
potentially associated with RLS (Table 2). Multivariable
analysis showed that fatigue before donation, hyperm-
enorrhaea and quality of life after donation were inde-
pendently associated with RLS (Table 3).
Discussion
In our study, the prevalence of clinically-relevant RLS in
female blood donors 1 week following blood donation
was 69%, which is similar to the prevalence observed in
the general population [1–5]. Female blood donors with
RLS had a higher prevalence of hypermenorrhaea and
reported significantly more fatigue. Nevertheless, there
was no association with the number of previous blood
donations and objectively measured physical fatigue. As
in several other studies [30], we found no correlation
between systemic iron status and RLS.
The strength of this study is that we not only assessed
RLS prevalence, but also many additional parameters. We
assessed menstrual bleeding and physical fatigue. We
compared haemoglobin, ferritin and fatigue before and
after blood donation. Clinical signs were assessed 1 week
after blood donation when haemoglobin and ferritin
values are consistently lower after blood donation.
As limitations, we were unable to compare RLS preva-
lence before and after donation because we did not plan
to measure it prior to blood donation. Given the small
number of donors involved and the low frequency of
RLS, an effect of low iron status could be missed since
the study is underpowered. Because we studied a healthy
population, it was not ethically acceptable to assess CSF
iron stock in our study population although this is of
interest since it is described as being decreased in patients
with RLS [10, 11, 31]. Because our study was transversal,
we cannot know if the fatigue was due to RLS or the
© 2013 International Society of Blood Transfusion
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opposite. The severity and duration of RLS were not stud-
ied. External validity only applied to female blood
donors. There was no non-blood donor control group.
Our results were significantly different from those of
the Swedish study that showed a RLS prevalence of
247% in female donors [15]. As pointed out by the
authors, the results were probably overestimated by meth-
odological problems, although they used the same criteria
as in our study. In a US study [17], the prevalence of RLS
in blood donors from both sexes was 9%, with a distinc-
tion between possible RLS (5%) and definite RLS (4%). In
our study, we also defined a possible RLS group that
included the population who described an ‘urge to move
the legs’ (first criterion) and not all three of the others.
The prevalence in this group was much higher (206%)
compared with the US study, but they did not use the
same tool to define the RLS and possible RLS groups
[32, 33]. It remains that this population could have a
milder or subclinical form of RLS, and further longitudi-
nal studies could be of interest to determine if some of
them develop RLS later on. Finally, contrary to the stud-
ies cited above, we measured RLS prevalence a week after
donation at the expected nadir of serum ferritin. We do
not know if that had an influence on the measured preva-
lence and whether it would have been different if we
Table 2 Population characteristics
No RLS (control)
n = 231
Possible RLS
n = 40
Clinical relevant RLS
n = 20 P-valuea
Age in years; average (range) 322 (18–49) 323 (18–51) 332 (18–50) 0912
Blood loss
Number of donations during previous 12 months;
average (SD)
09 (08) 07 (08) 09 (09) 0409
Pictorial bleeding assessment chart, >100; n (%) 69 (29%) 18 (45%) 10 (50%) 0033
Haematological
Haemoglobin in g/l
Before donation (same day); average (SD) 1336 (74) 1357 (83) 1352 (96) 0233
7 days after donation; average (SD) 1206 (74) 1231 (98) 1232 (78) 0087
Ferritin lg/l
Before donation (same day); average (SD) 370 (242) 394 (311) 367 (337) 0862
7 days after donation; average (SD) 176 (146) 186 (175) 221 (225) 0446
Fatigue
Chester step test, 7 days after donation (VO2 max);
average (SD)
366 (63) 362 (58) 349 (48) 0476
Fatigue severity scale (range 1–9)
Before donation (same day); average (SD) 26 (11) 32 (11) 33 (15) 0001
7 days after donation; average (SD) 32 (15) 41 (14) 41 (17) 0001
Health status (7 days after donation)
Depression PHQ-9; n (%) 5 (22%) 9 (225%) 1 (5%) <0001
SF-12 physical health (SD) 534 (43) 541 (46) 522 (61) 0356
SF-12 mental health (SD) 410 (54) 392 (69) 397 (55) 0169
ANOVA, analysis of variance; RLS, restless legs syndrome; SD, standard deviation; PHQ, Patient Health Questionnaire; SF, Short Form.
a
ANOVA or Fishers exact test.
Table 3 Predictors of restless legs syndrome, 7 days after blood dona-
tion
Odds ratio of having RLS
Crude
OR
Adjusteda
OR (95% CI; P-Value)
Pictorial bleeding
assessment chart >100
207 204 (108–390; P = 0029)
Haemoglobin after
donation <120 g/l
080 080 (041–154; P = 0501)
Fatigue Severity Scale
0–29 points (Reference) 1 1
3–39 points 158 156 (111–220; P = 0011)
4–49 points (SD) 281 243
5–59 points 563 380
Depression PHQ-9 904 –b
SF-12 mental health
≥35 points (reference) 1 1
30–34 points 204 148 (086–253; P = 0154)
20–29 points 340 219
OR, odds ratio; CI, confidence interval; SF, Short Form; PHQ, Patient
Health Questionnaire.
aFull data was available for 272 participants.
bPatient Health Questionnaire-9 was dropped due to co-linearity with
SF-12 mental health.
© 2013 International Society of Blood Transfusion
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looked for RLS a few weeks after blood donation. Other
studies are also needed.
The REST study [2], a general population study, showed
that the prevalence of RLS increases with age up to age
80 years then declines. RLS prevalence in younger
patients was lower than in our study. Thus, it remains
possible that the prevalence of RLS may be slightly
higher in blood donors compared with a general popula-
tion of the same age.
The RLS and possible RLS groups also reported signifi-
cantly more tiredness after blood donation than other
blood donors. A recent study found an association
between fatigue severity scores and heavy menstrual
bleeding in young women [34]. Therefore, it is important
to think of RLS among tired blood donors because RLS is
easy to diagnose with minimal cost, whereas investiga-
tions of fatigue can quickly generate significant costs.
Our study did not show any correlation between RLS
and haemoglobin and ferritin levels or the number of pre-
vious blood donations, which was already demonstrated
in previous studies [7, 15, 17, 18, 30, 35]. Recent studies
suggested that intravenous iron treatment improves the
symptoms of RLS in some patients [16, 30, 35, 36–38].
The correlation between hypermenorrhea and RLS found
in our study suggests that prolonged iron loss is more
predictive of RLS than systemic iron status and number
of previous donations. One explanation could be that
unlike menstruation, iron loss related to blood donation
probably does not happen on regular intervals throughout
a premenopausal woman’s life. Moreover, female blood
donors, who can donate twice a year, have often already
shown a good tolerance to successive blood donation.
Furthermore, systemic iron status does not reflect intrace-
rebral iron stores, which is reduced in the CNS of RLS
patients [10, 11, 31, 39]. The main hypothesis is that iron
deficiency in some brain regions (midbrain) would result
in a malfunction of the dopaminergic system leading to
symptoms of RLS [5, 40].
Genetic predisposition could also play a role as several
gene polymorphisms predictive of RLS have been identi-
fied [12, 41–44]. In the future, progress in this area could
even show that subjects genetically predisposed to RLS
are simply more sensitive than normal subjects to iron
deficiency.
In conclusion, we found that the RLS prevalence in
female blood donors is not as important as described in
some other studies. Therefore, our findings should reas-
sure blood donors. However, screening for fatigue and
hypermenorrhea should be considered as these symptoms
are associated with RLS in female blood donors.
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